Cargando…
Tumor-TME Bipartite Landscape of PD-1/PD-L1 in Endometrial Cancers
The bipartite landscape of tumor cells and stromal cells determines a tumor’s response to treatment during disease management. In endometrial cancers (ECs), the mechanistic contribution of PD-L1/L2 and PD-1 signaling of the host’s tumor microenvironment (TME) (CAF and immune cells) in the context of...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342322/ https://www.ncbi.nlm.nih.gov/pubmed/37446260 http://dx.doi.org/10.3390/ijms241311079 |
_version_ | 1785072471353851904 |
---|---|
author | Sulaiman, Raed De, Pradip Aske, Jennifer C. Lin, Xiaoqian Dale, Adam Koirala, Nischal Gaster, Kris Espaillat, Luis Rojas Starks, David Dey, Nandini |
author_facet | Sulaiman, Raed De, Pradip Aske, Jennifer C. Lin, Xiaoqian Dale, Adam Koirala, Nischal Gaster, Kris Espaillat, Luis Rojas Starks, David Dey, Nandini |
author_sort | Sulaiman, Raed |
collection | PubMed |
description | The bipartite landscape of tumor cells and stromal cells determines a tumor’s response to treatment during disease management. In endometrial cancers (ECs), the mechanistic contribution of PD-L1/L2 and PD-1 signaling of the host’s tumor microenvironment (TME) (CAF and immune cells) in the context of the tumor cells is elusive. To understand the tumor–stroma-immune crosstalk, we studied the compartmental pattern of PD-L1/L2 and PD-1 expression in EC tissues and their matched CAFs. Over 116 surgically resected tumors (T) and the tumor-adjacent normal tissues (N) were obtained from consented unselected consecutive patients. IHC was performed in T, N-epi-thelium, and the stromal mesenchymal environment (SME; mesenchyme) in the T and N tissues. The staining intensity and distribution patterns of PD-L1/L2 and PD-1 in the FFPE sections of T and N were evaluated by a pathologist using a standard scoring system of TPS and CPS. We tested the PD-L1/L2 and PD-1 immune landscape of tumor-TME pair and normal epithelial-stromal mesenchyme pairs from patients with different grades of disease vis-à-vis their CAF PD-L1 levels. We used qRT-PCR to determine the expressions of mRNAs, while the flow cytometry and ICC determined the level of expression of proteins. We observed higher levels of PD-L1 mRNA and protein expression in primary CAFs from the resected tumor tissue compared to the tumor-adjacent normal tissues. We also determined the expression of patients’ soluble PD-L1/L2 as peripheral readouts of PD-L1/L2 and PD-1. As we evaluated the results in the context of their pathological parameters, such as grades, stages, lymphovascular invasion, percentage of myometrial invasion, and dMMR in patients, the dominance of PD-L1 expression in TME was positively correlated to the higher pathological grades of tumors, and its relationship with the dMMR. Since the neutralization of CD8-positive cytotoxic T-cells is PD-L1-dependent, our data indicate that irrespective of the PD-L1 positivity of tumor cells, the PD-L1-positive CAFs can play a critical role in bringing out an additional load of PD-L1 for an effective engagement of PD-1 within a tumor mass. |
format | Online Article Text |
id | pubmed-10342322 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103423222023-07-14 Tumor-TME Bipartite Landscape of PD-1/PD-L1 in Endometrial Cancers Sulaiman, Raed De, Pradip Aske, Jennifer C. Lin, Xiaoqian Dale, Adam Koirala, Nischal Gaster, Kris Espaillat, Luis Rojas Starks, David Dey, Nandini Int J Mol Sci Article The bipartite landscape of tumor cells and stromal cells determines a tumor’s response to treatment during disease management. In endometrial cancers (ECs), the mechanistic contribution of PD-L1/L2 and PD-1 signaling of the host’s tumor microenvironment (TME) (CAF and immune cells) in the context of the tumor cells is elusive. To understand the tumor–stroma-immune crosstalk, we studied the compartmental pattern of PD-L1/L2 and PD-1 expression in EC tissues and their matched CAFs. Over 116 surgically resected tumors (T) and the tumor-adjacent normal tissues (N) were obtained from consented unselected consecutive patients. IHC was performed in T, N-epi-thelium, and the stromal mesenchymal environment (SME; mesenchyme) in the T and N tissues. The staining intensity and distribution patterns of PD-L1/L2 and PD-1 in the FFPE sections of T and N were evaluated by a pathologist using a standard scoring system of TPS and CPS. We tested the PD-L1/L2 and PD-1 immune landscape of tumor-TME pair and normal epithelial-stromal mesenchyme pairs from patients with different grades of disease vis-à-vis their CAF PD-L1 levels. We used qRT-PCR to determine the expressions of mRNAs, while the flow cytometry and ICC determined the level of expression of proteins. We observed higher levels of PD-L1 mRNA and protein expression in primary CAFs from the resected tumor tissue compared to the tumor-adjacent normal tissues. We also determined the expression of patients’ soluble PD-L1/L2 as peripheral readouts of PD-L1/L2 and PD-1. As we evaluated the results in the context of their pathological parameters, such as grades, stages, lymphovascular invasion, percentage of myometrial invasion, and dMMR in patients, the dominance of PD-L1 expression in TME was positively correlated to the higher pathological grades of tumors, and its relationship with the dMMR. Since the neutralization of CD8-positive cytotoxic T-cells is PD-L1-dependent, our data indicate that irrespective of the PD-L1 positivity of tumor cells, the PD-L1-positive CAFs can play a critical role in bringing out an additional load of PD-L1 for an effective engagement of PD-1 within a tumor mass. MDPI 2023-07-04 /pmc/articles/PMC10342322/ /pubmed/37446260 http://dx.doi.org/10.3390/ijms241311079 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Sulaiman, Raed De, Pradip Aske, Jennifer C. Lin, Xiaoqian Dale, Adam Koirala, Nischal Gaster, Kris Espaillat, Luis Rojas Starks, David Dey, Nandini Tumor-TME Bipartite Landscape of PD-1/PD-L1 in Endometrial Cancers |
title | Tumor-TME Bipartite Landscape of PD-1/PD-L1 in Endometrial Cancers |
title_full | Tumor-TME Bipartite Landscape of PD-1/PD-L1 in Endometrial Cancers |
title_fullStr | Tumor-TME Bipartite Landscape of PD-1/PD-L1 in Endometrial Cancers |
title_full_unstemmed | Tumor-TME Bipartite Landscape of PD-1/PD-L1 in Endometrial Cancers |
title_short | Tumor-TME Bipartite Landscape of PD-1/PD-L1 in Endometrial Cancers |
title_sort | tumor-tme bipartite landscape of pd-1/pd-l1 in endometrial cancers |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342322/ https://www.ncbi.nlm.nih.gov/pubmed/37446260 http://dx.doi.org/10.3390/ijms241311079 |
work_keys_str_mv | AT sulaimanraed tumortmebipartitelandscapeofpd1pdl1inendometrialcancers AT depradip tumortmebipartitelandscapeofpd1pdl1inendometrialcancers AT askejenniferc tumortmebipartitelandscapeofpd1pdl1inendometrialcancers AT linxiaoqian tumortmebipartitelandscapeofpd1pdl1inendometrialcancers AT daleadam tumortmebipartitelandscapeofpd1pdl1inendometrialcancers AT koiralanischal tumortmebipartitelandscapeofpd1pdl1inendometrialcancers AT gasterkris tumortmebipartitelandscapeofpd1pdl1inendometrialcancers AT espaillatluisrojas tumortmebipartitelandscapeofpd1pdl1inendometrialcancers AT starksdavid tumortmebipartitelandscapeofpd1pdl1inendometrialcancers AT deynandini tumortmebipartitelandscapeofpd1pdl1inendometrialcancers |